Related Experiment Video

Updated: Jun 19, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

CLA reduces breast cancer cell growth and invasion through ERalpha and PI3K/Akt pathways

C Bocca1, F Bozzo, S Cannito

  • 1Department of Experimental Medicine and Oncology, University of Torino, C.so Raffaello 30, 10125 Torino, Italy. claudia.bocca@unito.it

Chemico-Biological Interactions
|October 6, 2009
PubMed

Insights

Conjugated linoleic acid (CLA) inhibits breast cancer cell growth by down-regulating key signaling pathways like ERK/MAPK and PI3K/Akt. CLA also reduces cell invasion and migration, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Conjugated linoleic acid (CLA) is a naturally occurring fatty acid with previously reported anti-cancer properties.
  • CLA was shown to inhibit human breast cancer cell growth via modulation of the ERK/MAPK pathway and apoptosis induction.

Purpose of the Study:

  • To investigate the effects of CLA on additional signaling pathways in ERalpha(+) MCF-7 and ERalpha(-) MDA-MB-231 breast cancer cells.
  • To elucidate the mechanisms by which CLA affects cell signaling, cell adhesion, migration, and invasion.

Main Methods:

  • Cell culture of MCF-7 and MDA-MB-231 human breast cancer cell lines.
  • Analysis of signaling pathways including PI3K/Akt and ERK/MAPK.
  • Assessment of ERalpha phosphorylation, transcriptional activity, and complex formation with PP2A.
  • Evaluation of cell adhesion proteins, cell migration, and matrix metalloproteinase-2 (MMP-2) activity.

Main Results:

  • CLA down-regulates the PI3K/Akt cascade in both cell lines.
  • In MCF-7 cells, CLA induces ERalpha/PP2A complex formation, reducing ERalpha phosphorylation and activity; this effect was not observed in MDA-MB-231 cells.
  • CLA increases the expression of cell adhesion proteins and inhibits cell migration and MMP-2 activity.

Conclusions:

  • CLA exerts anti-cancer effects by modulating both kinase and phosphatase activities, impacting key signaling pathways.
  • CLA's ability to down-regulate ERalpha signaling and reduce cell invasion suggests a potential therapeutic role in breast cancer treatment.
  • The differential effect of CLA on PP2A activation in different breast cancer subtypes warrants further investigation.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...